hsa-mir-196a2 rs11614913 polymorphism contributes to cancer susceptibility evidence from 15 case-control studieshsa - mir - 196 - a2 rs11614913多态性有助于癌症易感性证据来自15个病例对照研究.pdfVIP

下载本文档

1
0
约 6页
2017-09-01 发布于上海
举报
版权申诉

hsa-mir-196a2 rs11614913 polymorphism contributes to cancer susceptibility evidence from 15 case-control studieshsa - mir - 196 - a2 rs11614913多态性有助于癌症易感性证据来自15个病例对照研究.pdf

1、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

hsa-mir-196a2 rs11614913 polymorphism contributes to cancer susceptibility evidence from 15 case-control studieshsa - mir - 196 - a2 rs11614913多态性有助于癌症易感性证据来自15个病例对照研究

Hsa-miR-196a2 RPolymorphism Contributes to Cancer Susceptibility: Evidence from 15 Case-Control Studies 1,2,3. 1,2,3. 1 1 1 1,2,3 1 Haiyan Chu , Meilin Wang , Danni Shi , Lan Ma , Zhizhong Zhang , Na Tong , Xinying Huo , 1 1 1 1,2,3 Wei Wang , Dewei Luo , Yan Gao , Zhengdong Zhang * 1Jiangsu Key Lab of Cancer Biomarkers, Prevention Treatment, Cancer Center, Nanjing Medical University, Nanjing, China, 2 The Key Laboratory of Modern Toxicology, Ministry of Education, Nanjing Medical University, Nanjing, China, 3 Department of Molecular Genetic Toxicology, School of Public Health, Nanjing Medical University, Nanjing, China Abstract Background: MicroRNAs (miRNAs) are a family of endogenous, small and noncoding RNAs that negatively regulate gene expression by suppressing translation or degrading mRNAs. Recently, many studies investigated the association between hsa-miR-196a2 rpolymorphism and cancer risk, which showed inconclusive results. Methodology/Principal Findings: We conducted a meta-analysis of 15 studies that included 9,341 cancer cases and 10,569 case-free controls. We assessed the strength of the association, using odds ratios (ORs) with 95% confidence intervals (CIs). Overall, individuals with the TC/CC genotypes were associated with higher cancer risk than those with the TT genotype (OR = 1.18, 95% CI = 1.03–1.34, P,0.001 for heterogeneity test). In the stratified analyses, we observed that the CC genotype might modulate breast cancer risk (OR = 1.11, 95%CI = 1.01–1.23, Pheterogeneity = 0.210) and lung cancer risk (OR = 1.25, 95%CI